Navigation Links
Biomarker may be an early predictor of advanced breast cancer
Date:11/5/2007

CINCINNATIResearchers have identified a molecule that may be more accurate than existing biological signposts used to predict which breast cancers will develop into advanced forms of the disease.

Detailed Oct. 24, 2007, in an early online edition of the International Journal of Cancer, the discovery could one day influence therapy decisions and prevent patients from unnecessarily undergoing aggressive cancer treatments.

When diagnosing breast cancer, pathologists currently look for elevated levels of three standard molecules known to make tumors grow in the breast. These moleculesestrogen receptor (ER), progesterone receptor (PR) and HER2are used as biomarkers for diagnosis and individually detect only a fraction of breast cancers.

The problem with these biomarkers is that many of them are present at some level in the normal breast, says Georg Weber, MD, PhD, lead investigator of the new study and associate professor of pharmacy at the University of Cincinnati. In addition, they are surface molecules that support growth so they are not necessarily a good predictor of tumor metastasis.

Weber and his team have identified a molecule, osteopontin-c, that is absent from the normal breast and appears to more accurately predict breast cancer that will become metastatic and spread to distant organs from the original tumor site.

In normal levels, osteopontin is a protein used by the immune system to help cells move and migrate. There are three forms of osteopontina, b and cwhich are formed by splicing, or cutting and pasting, ribonucleic acid (RNA) molecules to make variations of the original gene. Osteopontin-a is the normal form that helps with immune functions. Little is known about osteopontin-b, but if present its levels are very low. Osteopontin-c is the molecule Weber and his team discovered is a good biomarker of breast cancer.

In a two-year evaluation of 178 breast tumors, normal and abnormal tissue samples, they found that osteopontin-c was present in 78 percent of cancers and in 36 percent of the surrounding tissues. It was not detected at all in normal tissues.

In 56 breast cancers, 20 were positive and 36 were negative for estrogen receptor, 19 were positive and 37 were negative for progesterone receptor, and 26 were positive for HER2 with 30 negative.

Osteopontin-c was present in a substantially higher number of breast cancers than the three biomarkers traditionally used to diagnose breast cancer, says Weber. We also found that the cancers containing osteopontin-c correlated with a higher tumor grade, meaning they were more likely to become aggressive cancer.

If we know that this molecule is not present in a patient with breast cancer, its more likely that we can treat them with conservative therapy rather than breast surgery, hormone therapy or chemotherapy because we know its less likely to metastasize, he adds. On the other hand, if we know that a patient has this molecule early in their diagnosis, we can treat it more aggressively because we know their cancer is likely to become invasive.


'/>"/>

Contact: Jamie Davis Kaun
jamie.davis@uc.edu
513-558-4625
University of Cincinnati
Source:Eurekalert

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
3. Study makes progress in zoning in on biomarkers for better colon cancer treatment
4. New Ovarian Cancer Biomarker Research Act Introduced
5. Mayo Clinic study points to a possible biomarker for colon cancer in people 50 and under
6. Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
7. Pot bellies linked to early signs of cardiovascular disease
8. Eye-staining technique offers early detection for dry eye syndrome
9. Early Weight Loss in Women Linked to Dementia
10. Isolation of a new gene family essential for early development
11. U of M study: Early treatment can reverse heart damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
Breaking Medicine Technology: